Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 9, 1003-1009, October 2006; doi:10.1634/theoncologist.11-9-1003
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmoll, H.-J.
Right arrow Articles by Arnold, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmoll, H.-J.
Right arrow Articles by Arnold, D.

Special Section on Colorectal Cancer

Update on Capecitabine in Colorectal Cancer

Hans-Joachim Schmoll, Dirk Arnold

Department of Internal Medicine IV, Hematology & Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany

Key Words. Colorectal cancer • Capecitabine • Oxaliplatin • FOLFOX • CapOx • CapIri • XELOX

Correspondence: Hans-Joachim Schmoll, M.D., Ph.D., Department of Internal Medicine IV, Haematology & Oncology, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany. Telephone: + 49-345-557-2924; Fax: +49-345-557-2950; e-mail: hans-joachim. schmoll{at}medizin.uni-halle.de

In combination chemotherapy for metastatic colorectal cancer, i.v. 5-fluorouracil (5-FU) can be replaced by oral 5-FU (in the form of capecitabine or another orally available analogue) without negatively affecting overall toxicity and without remarkably reducing the efficacy of treatment in terms of response rate or overall survival. Preclinical evidence of synergy has led to promising early and successfully completed studies combining capecitabine plus oxaliplatin with bevacizumab, cetuximab, and epidermal growth factor receptor tyrosine kinase inhibitors. The use of preoperative capecitabine plus radiation is achieving good rates of pathological complete response in rectal cancer. While capecitabine is generally well tolerated, its potential toxicities need careful management and may require individual dose adaption.




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
R. N. Schwartz
Management of early and advanced colorectal cancer: Therapeutic issues
Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S8 - S14.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Lee, L. Johansen, Y. Zhang, A. Wilson, M. Keegan, W. Avery, P. Elliott, A. A. Borisy, and C. T. Keith
The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action
Cancer Res., December 1, 2007; 67(23): 11359 - 11367.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Johnston
The Colorectal Cancer Coalition: Reflections on the Future
Oncologist, October 1, 2006; 11(9): 970 - 972.
[Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg
Therapy for Metastatic Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 981 - 987.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement